On May 16, 2019, the pharmaceutical enterprise delegation organized by ACCIÓ visited China Pharmaceutical Innovation and Research Development Association (hereinafter referred to as PhIRDA). WANG Yinxiang, Chairman of PhIRDA Drug R&D Specialty Committee and Chairman of Beijing Jacobio Pharma Co., Ltd, ZHANG Dan, Vice-Chairman of Drug R&D Specialty Committee and Innovation R&D Services Specialty Committee, Chairman of Fountain Medical (Tianjin) Co., Ltd, and LU Xiaoti, Deputy Secretary-General of PhIRDA, extended a warm welcome to ACCIÓ Delegation and made fruitful communication on current status of pharmaceutical industry, drug review and approval regulations and reforms in China, as well as the pharmaceutical industry in Catalonia.
Plenary Meeting
Dr. WANG Yinxiang and Dr. ZHANG Dan made full introductions of the development of pharmaceutical industry and the reform of drug regulatory policy in China. ACCIÓ Delegation was impressed by the in-depth reform in China and made productive exchanges with PhIRDA experts on clinical trial management, drug approval process, Sino-European business cooperation, etc.. Ms. LU Xiaoti made introduction of PhIRDA and 2019 China BioMed Innovation and Investment Conference (2019 CBIIC) as well, and Ms. Isabel Gimeno, Director of Asia-Pacific Dept. of ACCIÓ, showed great interest in the event and would organize Spanish pharmaceutical enterprises to participated in it.
Representatives from EIGNA Pharma, ANAGRAM, Imagen Ensayos Clinicos, CYTES and Lab Rubio in Catalonia introduced the companies and potential cooperation field respectively, making a heated discussion with PhIRDA experts on Chinese pharmaceutical market, Sino-European pharmaceutical policy environment and other related issues.
Representatives of ACCIÓ Delegation and PhIRDA
Recent years, Chinese government issued and published a series of encouraging reform policies, greatly accelerating the development of biopharmaceutical innovation in China. ACCIÓ would like to strengthen collaboration with PhIRDA to help Spanish pharmaceutical companies to seek potential partners in China, deepening the biopharmaceutical cooperation between China and Spain and jointly promote the bilateral the pharmaceutical industry innovation.
The meeting was attended by GAO Wei, Chief Representative of ACCIÓ Beijing Office, Ángels Carrió, CEO of EIGNA Pharma, Silvia Casellas, CEO of ANAGRAM Co., Ltd., José Mateos, CEO of Imagen Ensayos Clinicos (IEC) Co., Ltd., Estephan Arredondo, Technical Director of CYTES Biotechnologies Co., Ltd., Imma Abella, Business Unit Director of Lab Rubio Co., Ltd., RUAN Xinxin, Deputy Director of International Affairs of PhIRDA, YANG Yuanlin, Project Manager of International Affairs of PhIRDA.